http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 19 Feb 2026 16:16:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+19/26030097.html si-local-file:///var/storage/secattach/20260219/26030097.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+19/26030097.html Thu, 19 Feb 2026 16:16:00 -0500 BIO O.00005917 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+19/26030097.html si-local-file:///var/storage/secattach/20260219/26030097.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+19/26030097.html Thu, 19 Feb 2026 16:16:00 -0500 BIO O.00005917 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Dec+31/25994972.html si-local-file:///var/storage/secattach/20260213/25994972.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Dec+31/25994972.html Fri, 13 Feb 2026 06:06:00 -0500 BIO O.00005917 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Dec+31/25994972.html si-local-file:///var/storage/secattach/20260213/25994972.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Dec+31/25994972.html Fri, 13 Feb 2026 06:06:00 -0500 BIO O.00005917 http://www.streetinsider.com/Earnings/Bio-Rad+Labs+%28BIO%29+Misses+Q4+EPS+by+20c%3B+offers+outlook/25992150.html <p>Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.51, $0.20 worse than the analyst estimate of $2.71. Revenue for the quarter came in at $693.2 million versus the consensus estimate of $692.96 million.</p><p><strong>Full-Year 2026 Financial Outlook</strong></p><p>Bio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5 percent and an estimated non-GAAP operating margin of approximately 12.0 to 12.5 percent.</p><p>For earnings history and earnings-related data on Bio-Rad Labs (BIO) <a href="http://www.streetinsider.com/ec_earnings.php?q=BIO">click here</a>.</p> http://www.streetinsider.com/Earnings/Bio-Rad+Labs+%28BIO%29+Misses+Q4+EPS+by+20c%3B+offers+outlook/25992150.html Thu, 12 Feb 2026 16:16:53 -0500 BIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+12/25992155.html si-local-file:///var/storage/secattach/20260212/25992155.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+12/25992155.html Thu, 12 Feb 2026 16:16:00 -0500 BIO O.00005917 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+12/25992155.html si-local-file:///var/storage/secattach/20260212/25992155.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIO-RAD+LABORATORIES%2C+++++For%3A+Feb+12/25992155.html Thu, 12 Feb 2026 16:16:00 -0500 BIO O.00005917 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Press+Releases/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637 http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html <p> HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. </p><p> Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are http://www.streetinsider.com/Business+Wire/Bio-Rad+Reports+Fourth-Quarter+and+Full-Year+2025+Financial+Results/25992083.html Thu, 12 Feb 2026 16:15:00 -0500 A.29655321 A.50210587 A.50216269 BIO BIO.B O.00005917 O.05058026 O.14972255 O.23727637